May 12, 2022
2 min watch
Save
VIDEO: EyePoint shares 8- and 9-month data on wet AMD treatment
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress here, Nancy Lurker, president and CEO of EyePoint Pharmaceuticals, discusses the latest update on EYP-1901.
The 8- and 9-month data from the phase 1 DAVIO trial of EYP-1901 for the treatment of wet age-related macular degeneration showed very good safety and efficacy, according to Lurker.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Lurker reports being president and CEO of EyePoint Pharmaceuticals.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.